• Enanta Pharmaceuticals flagged new Phase 2 results for RSV drug candidate zelicapavir, scheduled for presentation at IDWeek 2026.
• Trial data indicate faster symptom resolution, fewer hospitalizations, lower viral burden versus placebo in high-risk adults.
• Presentation is set for Oct. 22, 2026, positioning zelicapavir as a potential once-daily oral option in RSV.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261013575271) on October 13, 2026, and is solely responsible for the information contained therein.